PharmAust can now assess dosing strategies for the upcoming Phase II clinical trials for its anti-cancer drug Monepantel in dogs after receiving further positive results from the ongoing Phase I trial. Serum levels of both Monepantel and its major metabolite, monepantel sulfone, exceeded the predicted anti-cancer activity target values in dogs administered just one tablet per day.
06/05/2019 - 13:37
PharmAust cancer drug trials making good progress
By Matt Birney
06/05/2019 - 13:37
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX